SPOTLIGHT: Schizophrenia drugs don't cut aggression


In a journal article sure to fuel the already-fierce debate over antipsychotic drugs, new research shows that placebo may be more effective at managing aggression in intellectually disabled patients. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.